The Associated Press
January 20, 2004
NEW YORK—
Here is a chornology of events in the
Martha Stewart stock-trading case:
Oct. 31, 2001: ImClone Systems Inc. asks government to review Erbitux, its new cancer drug.
- Related
-
Name: Martha Helen Stewart. (Born Martha Helen Kostyra.)
Age: 62.
Hometown: Nutley, N.J.
Education: Bachelor's degree in history and architectural history, Barnard College.
Career: Stockbroker, 1968-73. Started a catering business in Westport, Conn., in 1972. Published her first book, "Entertaining," in 1982. Time Inc. began publishing Martha Stewart Living magazine in 1991. Syndicated TV show "Martha Stewart Living" began airing in 1992. Bought her business away from Time in 1997, naming it Martha Stewart Living Omnimedia Inc. Took company public in 1999. Resigned as chairman and CEO on June 4, 2003, but remained on board and as chief creative officer.
Quote: "I want you to know that I am innocent -- and that I will fight to clear my name."
-- The Associated Press
-
Martha Stewart poll
Martha Stewart poll
-
Douglas Faneuil listens to his attorney outside court
-
Video
-
Shades of Stewart
-
The history of a controversy
-
Martha Stewart Preliminary Hearing
-
See more stories »
-
Topics
-
Justice System
-
ImClone Systems Incorporated
-
Punishment
-
See more topics »
Dec. 26, 2001: ImClone founder Samuel D. Waksal is tipped that the government will reject Erbitux application, then tips his daughter to sell her ImClone stock and tries to sell his own.
Dec. 27, 2001: Stewart sells all 3,928 shares of her ImClone stock at about $58.43 each, or a total of $228,000. The government later contends she was tipped that Waksal was trying to sell his shares.
Dec. 28, 2001: U.S. Food and Drug Administration makes Erbitux decision public. On Dec. 31, the first trading day after the news, ImClone drops 18 percent.
Jan. 7, 2002: Stewart's broker, Peter Bacanovic, tells Securities and Exchange Commission attorneys that he and Stewart had agreed on Dec. 20, 2001, to sell ImClone if it fell below $60.
Feb. 4, 2002: Stewart gives SEC, federal prosecutors and FBI the same account.
June 12, 2002: Waksal is arrested and charged with insider trading. Stock in Stewart's company falls 5.6 percent. In a statement, Stewart repeats her assertion that she had a standing agreement to sell at $60.
June 18, 2002: Stewart insists she is "fully" cooperating.
Oct. 2, 2002: Former Merrill Lynch & Co. assistant Doug Faneuil pleads guilty to taking payoff to keep quiet about Stewart stock trade.
Oct. 15, 2002: Waksal admits tipping his daughter to sell ImClone ahead of FDA decision and trying to sell his own shares.
June 4, 2003: Stewart and Bacanovic are indicted. Both plead innocent. Stewart resigns as chairwoman and CEO of her company but remains chief creative officer and board member.
June 5, 2003: Stewart introduces personal Web site in which she proclaims her innocence and insists she will fight to clear her name.
June 10, 2003: Waksal is sentenced to more than seven years in prison.
Nov. 7, 2003: Stewart says in ABC interview that she is scared of prison but "I don't think I will be going to prison."
Nov. 18, 2003: U.S. District Judge Miriam Goldman Cedarbaum rejects Stewart's request to throw out two of five charges, including controversial securities fraud count.
Jan. 6, 2004: Potential jurors fill out questionnaire. It reportedly asks whether they have visited Stewart's Web site or cooked with her recipes.
Jan. 20, 2004: Stewart and Bacanovic arrive for juror questioning.
